Cytosorbents (CTSO)
(Delayed Data from NSDQ)
$1.55 USD
+0.13 (9.15%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.53 -0.02 (-1.29%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Cytosorbents Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 36 | 35 | 43 | 41 | 25 |
Cost Of Goods | 14 | 14 | 11 | 11 | 7 |
Gross Profit | 22 | 21 | 32 | 30 | 18 |
Selling & Adminstrative & Depr. & Amort Expenses | 54 | 52 | 55 | 40 | 37 |
Income After Depreciation & Amortization | -31 | -32 | -23 | -10 | -19 |
Non-Operating Income | 2 | -2 | -3 | 1 | -1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -29 | -34 | -25 | -9 | -20 |
Income Taxes | -1 | -1 | -1 | -1 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -29 | -33 | -25 | -8 | -19 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -29 | -33 | -25 | -8 | -19 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -29 | -30 | -22 | -9 | -18 |
Depreciation & Amortization (Cash Flow) | 2 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -31 | -32 | -23 | -10 | -19 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 44.66 | 43.57 | 43.36 | 38.82 | 32.26 |
Diluted EPS Before Non-Recurring Items | -0.64 | -0.75 | -0.57 | -0.20 | -0.60 |
Diluted Net EPS (GAAP) | -0.64 | -0.75 | -0.57 | -0.20 | -0.60 |
Fiscal Year end for Cytosorbents Corporation falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 9.89 | 9.79 | 8.67 | 8.81 | 9.42 |
Cost Of Goods | 3.39 | 3.22 | 3.36 | 3.20 | 3.40 |
Gross Profit | 6.50 | 6.57 | 5.31 | 5.61 | 6.02 |
SG&A, R&D, and Dept/Amort Expenses | 9.92 | 11.50 | 14.72 | 12.96 | 12.58 |
Income After SG&A, R&D, and Dept/Amort Expenses | -3.42 | -4.93 | -9.41 | -7.35 | -6.56 |
Non-Operating Income | -0.72 | -1.43 | 2.76 | -1.84 | 0.41 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -4.14 | -6.36 | -6.65 | -9.19 | -6.15 |
Income Taxes | 0.00 | 0.00 | -0.81 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -4.14 | -6.36 | -5.83 | -9.19 | -6.15 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -4.14 | -6.36 | -5.83 | -9.19 | -6.15 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 54.31 | 54.26 | 44.66 | 44.37 | 44.02 |
Diluted EPS Before Non-Recurring Items | -0.08 | -0.12 | -0.12 | -0.21 | -0.14 |
Diluted Net EPS (GAAP) | -0.08 | -0.12 | -0.12 | -0.21 | -0.14 |